Oncology

The 2018 oncology drug market had a record number of new treatments and continued a trend of growth.

Investigational oral MET kinase inhibitor from Merck.

CD20-directed antibody indicated for several cancers and other conditions.

First oral drug for advanced or metastatic bladder cancer.

Nuclear export inhibitor indicated in combination with dexamethasone.

Now approved to be used in combiantion with lenalidomide and dexamethasone. 

Bevacizumab-bvzr is an mAb endothelial growth factor biosimilar.

New features to ease injection administration. 

Indications include breast cancer, metastatic gastric cancer, and metastatic gastroesophageal junction adenocarcinoma.

This thalidomide analogue is also indicated for multiple myeloma and myelodysplastic syndromes.

Venetoclax, a BCL-2 inhibitor first approved in 2016, is now indicated for chronic lymphocytic leukemia and small lymphocytic lymphoma.

Approval marks the first anti-PD-L1 therapy combination for RCC.

New indication joins a series of single-agent and combination treatments for various cancers.

Tibsovo (ivosidenib) is an isocitrate dehydrogenase1- inhibitor, originally approved in 2018.

The FDA has recently approved new dosage form and two new indications for the drug. 

Erdafitinib is first targeted therapy for FGFR3 or FGFR2 genetic alteration.

Indicated for breast cancer, and gastric or gastroesophageal junction adenocarcinoma. 

The report by Magellan Rx Management indicates PMPM, site of service, and Medicaid prices continue to increase. 

Approved by the FDA in September, this new drug serves as a first-line therapy for patients with particular metastatic non-small lung cancer.

Patients with atrial fibrillation who have had cancer are less likely to see a cardiologist and less likely to fill anticoagulant prescriptions.

Oncology pharmacists have a challenging job caring for cancer patients.